Anastasios Kyriazoglou Selected Research

Guillain-Barre Syndrome

1/2019

Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anastasios Kyriazoglou Research Topics

Disease

10	Neoplasms (Cancer) 01/2023 - 01/2019
5	Sarcoma (Soft Tissue Sarcoma) 01/2023 - 12/2018
4	Breast Neoplasms (Breast Cancer) 11/2022 - 12/2019
3	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 06/2022 - 01/2019
3	Ovarian Neoplasms (Ovarian Cancer) 04/2022 - 01/2020
2	Ewing Sarcoma (Sarcoma, Ewing) 01/2023 - 06/2019
2	Osteosarcoma (Osteogenic Sarcoma) 01/2023 - 04/2021
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2023 - 04/2022
2	Carcinogenesis 06/2022 - 05/2021
2	Leiomyosarcoma 05/2021 - 04/2021
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 09/2019 - 05/2019
1	Primitive Neuroectodermal Tumors (PNET) 01/2023
1	Squamous Cell Carcinoma of Head and Neck 01/2023
1	Carcinoma (Carcinomatosis) 04/2022
1	Disease Progression 04/2022
1	Arthralgia (Joint Pain) 04/2022
1	Nasopharyngeal Carcinoma 12/2021
1	Brain Neoplasms (Brain Tumor) 12/2021
1	Endometrial Stromal Sarcoma 05/2021
1	Musculoskeletal Pain 01/2021
1	Necrosis 01/2020
1	Ovarian Epithelial Carcinoma 01/2020
1	Epithelioid Hemangioendothelioma 01/2020
1	Spontaneous Abortion (Miscarriage) 09/2019
1	Guillain-Barre Syndrome 01/2019
1	Lung Neoplasms (Lung Cancer) 04/2018
1	Tooth Erosion 07/2014

Drug/Important Bio-Agent (IBA)

4	cabozantinibIBA 01/2023 - 01/2021
3	NivolumabIBA 01/2023 - 04/2018
3	Immune Checkpoint InhibitorsIBA 04/2022 - 01/2021
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 04/2018
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 05/2021
2	Proteins (Proteins, Gene)FDA Link 06/2022 - 05/2021
2	Cyclin D1IBA 05/2021 - 01/2019
2	Imatinib Mesylate (Gleevec)FDA Link 01/2019 - 07/2014
1	Circulating Tumor DNAIBA 01/2023
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2023
1	Everolimus FDA Link 01/2023
1	Cell-Free Nucleic AcidsIBA 01/2023
1	Axitinib (AG 013736)IBA 01/2023
1	DNA (Deoxyribonucleic Acid)IBA 01/2023
1	4-azidobenzylcarazolol (pABC)IBA 11/2022
1	Tyrosine Kinase InhibitorsIBA 06/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2022
1	Methotrexate (Mexate)FDA LinkGeneric 04/2022
1	Bevacizumab (Avastin)FDA Link 04/2022
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2022
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022
1	Oncogene Proteins (Oncogene Protein)IBA 05/2021
1	ripretinibIBA 01/2021
1	avapritinibIBA 01/2021
1	Aromatase InhibitorsIBA 01/2021
1	Hormones (Hormone)IBA 01/2021
1	olaratumabIBA 01/2020
1	MicroRNAs (MicroRNA)IBA 12/2019
1	PlatinumIBA 09/2019
1	Taxoids (Taxanes)IBA 09/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2019
1	130-nm albumin-bound paclitaxelIBA 04/2018
1	RamucirumabIBA 04/2018
1	durvalumabIBA 04/2018
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2018
1	pembrolizumabIBA 04/2018
1	AfatinibIBA 04/2018
1	necitumumabIBA 04/2018
1	atezolizumabIBA 04/2018
1	ErbB Receptors (EGF Receptor)IBA 04/2018

Therapy/Procedure

12	Therapeutics 01/2023 - 07/2014
8	Drug Therapy (Chemotherapy) 01/2023 - 04/2018
5	Immunotherapy 02/2022 - 04/2018
2	Radiotherapy 04/2021 - 06/2019
1	Off-Label Use 01/2023
1	Chemoradiotherapy 01/2023
1	Neoadjuvant Therapy 01/2020
1	Palliative Care (Palliative Therapy) 12/2018